

Guard Therapeutics presents the Nomination Committee for 2024

Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.

According to previous AGM resolutions, a Nomination Committee shall be appointed for the election and remuneration of the Board of Directors. The Nomination Committee shall consist of four members – one representative of each of the three largest shareholders who have accepted the assignment and the Chairman of the Board.

The Nomination Committee has now been appointed and consists of the following members:

- Jan Ståhlberg, representing own holdings
- Mia Arnhult, representing M2 Asset Management
- Peter Wolpert, representing Stiftelsen Industrifonden
- Johan Bygge, Chairman of the Board

Prior to the 2024 Annual General Meeting, the Nomination Committee shall submit proposals for; chairman of the annual general meeting, number of board members elected by the AGM, chairman and other members of the board elected by the AGM, fees and other remuneration to each of the board members elected by the AGM and to members of the board's committees (where applicable), number of auditors, auditors, fees to auditors and election of the nomination committee (alternatively, a decision on principles for the appointment of the Nomination Committee, as well as a decision on instructions for the Nomination Committee in cases where the Nomination Committee considers that the applicable principles and instructions should be updated). The Nomination Committee's proposals will be presented in the notice convening the Annual General Meeting 2024.

For further information, please contact:

Johan Bygge, Chairman of the Board

Telephone: +46 8 670 65 51

E-mail: info@guardtherapeutics.com

Press Release
07 December 2023 12:00:00 CET



About Guard Therapeutics

Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company's investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, www.skmg.se.

Attachments

[Guard Therapeutics presents the Nomination Committee for 2024](#)